Literature DB >> 22674643

Prevalence of primary immune thrombocytopenia in Oklahoma.

Deirdra R Terrell1, Laura A Beebe, Barbara R Neas, Sara K Vesely, Jodi B Segal, James N George.   

Abstract

To determine the prevalence of immune thrombocytopenia (ITP) in Oklahoma regardless of age, clinical characteristics, insurance status, and source of health care. Patients with ITP were identified by the administrative code ICD-9-CM 287.3 in Oklahoma hematologists' offices for a 2-year period, 2003-2004. Prevalence was estimated separately for children (<16 years old) and adults because of their distinct clinical characteristics. Oklahoma census data for 2000 was used as the denominator. Eighty-seven (94%) of 93 eligible Oklahoma hematologists participated; 620 patients with ITP were identified. The average annual prevalences were as follows: 8.1 (95% CI: 6.7-9.5) per 100,000 children, 12.1 (95% CI: 11.1-13.0) per 100,000 adults, and 11.2 (95% CI: 10.4-12.0) per 100,000 population. Among children and adults less than age 70 years, the prevalence was greater among women. Among adults aged 70 years and older, the prevalence was greater among men. The highest prevalence of ITP was among men age 80 years and older. These data document for the first time the prevalence of ITP regardless of age, clinical characteristics, insurance status, and source of health care. The methodology developed for this prevalence analysis may be adaptable for epidemiologic studies of other uncommon disorders which lack specific diagnostic criteria and are treated primarily by medical specialists. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22674643      PMCID: PMC3429719          DOI: 10.1002/ajh.23262

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  27 in total

1.  Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.

Authors:  J E Portielje; R G Westendorp; H C Kluin-Nelemans; A Brand
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

2.  Referral of patients with thrombocytopenia from primary care clinicians to hematologists.

Authors:  Deirdra R Terrell; Laura A Beebe; James N George; Sara K Vesely; James W Mold
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration.

Authors:  B Zeller; J Helgestad; M Hellebostad; S Kolmannskog; T Nystad; K Stensvold; F Wesenberg
Journal:  Pediatr Hematol Oncol       Date:  2000 Oct-Nov       Impact factor: 1.969

5.  Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome.

Authors:  M M Reid
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

6.  Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

Authors:  James N George; Susan D Mathias; Ronald S Go; Matthew Guo; David H Henry; Roger Lyons; Robert L Redner; Lawrence Rice; Martin R Schipperus
Journal:  Br J Haematol       Date:  2008-11-11       Impact factor: 6.998

7.  Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey.

Authors:  Claire F Snyder; Susan D Mathias; David Cella; John J Isitt; Albert W Wu; Joan Young
Journal:  Curr Med Res Opin       Date:  2008-08-19       Impact factor: 2.580

8.  Idiopathic thrombocytopenic purpura diagnosed during the second decade of life.

Authors:  Eric J Lowe; George R Buchanan
Journal:  J Pediatr       Date:  2002-08       Impact factor: 4.406

9.  Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study.

Authors:  Jodi B Segal; Neil R Powe
Journal:  Am J Hematol       Date:  2004-01       Impact factor: 10.047

Review 10.  Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.

Authors:  Annette J Neylon; Peter W G Saunders; Martin R Howard; Stephen J Proctor; Penelope R A Taylor
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

View more
  18 in total

1.  Immune thrombocytopenia: getting back to basics.

Authors:  Donald M Arnold
Journal:  Am J Hematol       Date:  2012-07-05       Impact factor: 10.047

Review 2.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

3.  Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry.

Authors:  Elizabeth J Feuille; Niloofar Anooshiravani; Kathleen E Sullivan; Ramsay L Fuleihan; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2017-10-28       Impact factor: 8.317

Review 4.  Chinese guidelines for treatment of adult primary immune thrombocytopenia.

Authors:  Xin-Guang Liu; Xiao-Chuan Bai; Fang-Ping Chen; Yun-Feng Cheng; Ke-Sheng Dai; Mei-Yun Fang; Jian-Ming Feng; Yu-Ping Gong; Tao Guo; Xin-Hong Guo; Yue Han; Luo-Jia Hong; Yu Hu; Bao-Lai Hua; Rui-Bing Huang; Yan Li; Jun Peng; Mi-Mi Shu; Jing Sun; Pei-Yan Sun; Yu-Qian Sun; Chun-Sen Wang; Shu-Jie Wang; Xiao-Min Wang; Cong-Ming Wu; Wen-Man Wu; Zhen-Yu Yan; Feng-E Yang; Lin-Hua Yang; Ren-Chi Yang; Tong-Hua Yang; Xu Ye; Guang-Sen Zhang; Lei Zhang; Chang-Cheng Zheng; Hu Zhou; Min Zhou; Rong-Fu Zhou; Ze-Ping Zhou; Hong-Li Zhu; Tie-Nan Zhu; Ming Hou
Journal:  Int J Hematol       Date:  2018-04-04       Impact factor: 2.490

5.  Determining a definite diagnosis of primary immune thrombocytopenia by medical record review.

Authors:  Deirdra R Terrell; Laura A Beebe; Sara K Vesely; Barbara R Neas; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-20       Impact factor: 10.047

Review 6.  Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race.

Authors:  Melissa H Roberts; Esther Erdei
Journal:  Autoimmun Rev       Date:  2019-11-14       Impact factor: 9.754

Review 7.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

Review 8.  Positioning new treatments in the management of immune thrombocytopenia.

Authors:  Donald M Arnold
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

9.  Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.

Authors:  Xin-Guang Liu; Ming Hou
Journal:  Open Med (Wars)       Date:  2016-04-18

10.  Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.

Authors:  Jiaxing Zhang; Yi Liang; Yuan Ai; Xiaosi Li; Juan Xie; Youping Li; Wenyi Zheng; Rui He
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.